Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges

Vitaly P. Pozharov, Tamara Minko

Research output: Contribution to journalReview articlepeer-review


Over the past decades, many drugs based on the use of nanotechnology and nucleic acids have been developed. However, until recently, most of them remained at the stage of pre-clinical development and testing and did not find their way to the clinic. In our opinion, the main reason for this situation lies in the enormous complexity of the development and industrial production of such formulations leading to their high cost. The development of nanotechnology-based drugs requires the participation of scientists from many and completely different specialties including Pharmaceutical Sciences, Medicine, Engineering, Drug Delivery, Chemistry, Molecular Biology, Physiology and so on. Nevertheless, emergence of coronavirus and new vaccines based on nanotechnology has shown the high efficiency of this approach. Effective development of vaccines based on the use of nucleic acids and nanomedicine requires an understanding of a wide range of principles including mechanisms of immune responses, nucleic acid functions, nanotechnology and vaccinations. In this regard, the purpose of the current review is to recall the basic principles of the work of the immune system, vaccination, nanotechnology and drug delivery in terms of the development and production of vaccines based on both nanotechnology and the use of nucleic acids.

Original languageEnglish (US)
Article number194
Issue number1
StatePublished - Jan 2023

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science


  • RNA
  • coronavirus
  • immunity
  • nanomedicine
  • nanotechnology
  • vaccine


Dive into the research topics of 'Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges'. Together they form a unique fingerprint.

Cite this